Literature DB >> 11914215

Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.

S R Boyd1, D S W Tan, L de Souza, M H Neale, N E Myatt, R A Alexander, M Robb, J L Hungerford, I A Cree.   

Abstract

BACKGROUND: Tumour microvascularity is a significant determinant of prognosis for a large number of different tumours, including uveal melanoma. The development of blood vessels within these and other tumours is partly controlled by soluble pro-angiogenic cytokines, of which basic fibroblast growth factor (bFGF) and vascular endothelial growth factor-A (VEGF) are the best described.
METHODS: Because VEGF has been inconsistently found within uveal melanomas and bFGF is described as an autocrine growth factor in cutaneous melanoma, the authors looked at the expression of these cytokines in uveal melanomas using immunohistochemistry and reverse transcriptase polymerase chain reaction (RT-PCR). The cross talk between uveal melanoma cells and endothelial cells was then assessed in an in vitro co-culture model.
RESULTS: While most tumour cells expressed bFGF at the protein level by immunohistochemistry (89%), relatively few (22%) expressed VEGF, and this was of limited extent. All 20 tumours tested by RT-PCR contained mRNA for both bFGF and VEGF. Co-culture experiments using an ATP based bioassay showed that uveal melanomas could support the growth of a rat brain endothelial cell line (GPNT) and human umbilical vein endothelial cells (HUVEC), and that this could be modulated by cytokines and anti-cytokine antibodies.
CONCLUSION: These results suggest that angiogenesis within uveal melanoma may be the result of a complex interplay between endothelial and tumour cells, and that bFGF and VEGF could play a part.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914215      PMCID: PMC1771075          DOI: 10.1136/bjo.86.4.440

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  57 in total

1.  Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines.

Authors:  S A Ijland; M J Jager; B M Heijdra; J R Westphal; R Peek
Journal:  Melanoma Res       Date:  1999-10       Impact factor: 3.599

2.  What is the evidence that tumors are angiogenesis dependent?

Authors:  J Folkman
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

3.  Evaluation of measurement of human TNF in plasma by ELISA.

Authors:  I Engelberts; A Möller; G J Schoen; C J van der Linden; W A Buurman
Journal:  Lymphokine Cytokine Res       Date:  1991-04

4.  Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis.

Authors:  T G Sheidow; P L Hooper; C Crukley; J Young; J G Heathcote
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

5.  Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes.

Authors:  U Rodeck; K Melber; R Kath; H D Menssen; M Varello; B Atkinson; M Herlyn
Journal:  J Invest Dermatol       Date:  1991-07       Impact factor: 8.551

6.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.

Authors:  D Hanahan
Journal:  Nature       Date:  1985 May 9-15       Impact factor: 49.962

7.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

8.  Quantitation of the granuloma fraction in leprosy skin biopsies by planimetry.

Authors:  I A Cree; A C McDougall; G Coghill; J S Beck
Journal:  Int J Lepr Other Mycobact Dis       Date:  1985-12

9.  Angiogenesis capacity as a diagnostic marker for human eye tumors.

Authors:  D Tapper; R Langer; A R Bellows; J Folkman
Journal:  Surgery       Date:  1979-07       Impact factor: 3.982

10.  Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment.

Authors:  G P Dotto; G Moellmann; S Ghosh; M Edwards; R Halaban
Journal:  J Cell Biol       Date:  1989-12       Impact factor: 10.539

View more
  14 in total

1.  A pilot study of bevacizumab and interferon-α2b in ocular melanoma.

Authors:  Kristan D Guenterberg; Valerie P Grignol; Kiran V Relekar; Kimberly A Varker; Helen X Chen; Kari L Kendra; Thomas E Olencki; William E Carson
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

2.  Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival.

Authors:  Alexandra Giatromanolaki; Efthimios Sivridis; Nikolaos E Bechrakis; Gregor Willerding; Georgios St Charitoudis; Michael H Foerster; Kevin C Gatter; Adrian L Harris; Michael I Koukourakis
Journal:  Clin Exp Metastasis       Date:  2011-10-09       Impact factor: 5.150

3.  Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: A meta-analysis.

Authors:  Meng Yang; Xiaocong Kuang; Yanbin Pan; Meile Tan; Binzhu Lu; Jian Lu; Qiumei Cheng; Jianmin Li
Journal:  Mol Clin Oncol       Date:  2014-01-22

4.  Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.

Authors:  Armelle Calipel; Solange Landreville; Arnaud De La Fouchardière; Frédéric Mascarelli; Michel Rivoire; Nicolas Penel; Frédéric Mouriaux
Journal:  Clin Exp Metastasis       Date:  2014-03-21       Impact factor: 5.150

5.  Serial Intravitreal Bevacizumab Injections Slow the Progression of Radiation Maculopathy Following Iodine-125 Plaque Radiotherapy.

Authors:  Andrew W Stacey; Hakan Demirci
Journal:  Open Ophthalmol J       Date:  2016-03-15

6.  High-Dose (2.5 mg) Intravitreal Bevacizumab as Rescue Therapy for Persistent Postradiation Cystoid Macular Edema.

Authors:  Mohammed Ali Khan; Arman Mashayekhi; Kyle Ferguson; Jerry A Shields; Carol L Shields
Journal:  Ocul Oncol Pathol       Date:  2017-01-27

7.  Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines.

Authors:  Patrick Logan; Julia Burnier; Miguel N Burnier
Journal:  Ecancermedicalscience       Date:  2013-07-31

8.  Subtoxic Levels of Apigenin Inhibit Expression and Secretion of VEGF by Uveal Melanoma Cells via Suppression of ERK1/2 and PI3K/Akt Pathways.

Authors:  Shih-Chun Chao; Sheng-Chieh Huang; Dan-Ning Hu; Hung-Yu Lin
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-31       Impact factor: 2.629

9.  Construction of a human monoclonal antibody against bFGF for suppression of NSCLC.

Authors:  Sheng Wang; Yiyang Qin; Zhongmin Wang; Junjian Xiang; Yu Zhang; Meng Xu; Baiyong Li; Yu Xia; Peng Zhang; Hong Wang
Journal:  J Cancer       Date:  2018-04-30       Impact factor: 4.207

10.  Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid.

Authors:  Junwon Lee; Hee Jung Kwon; Min Kim; Christopher Seungkyu Lee; Sung Chul Lee
Journal:  BMC Ophthalmol       Date:  2019-05-03       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.